Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Acute transverse myelitis following Japanese encephalitis viral infection: an uncommon complication of a common disease.
Vitamin D - immunomodulatory actions and new potentialities.
The pathogenic role of the inflammasome in neurodegenerative diseases.
Axonal loss in non-optic neuritis eyes of patients with multiple sclerosis linked to delayed visual evoked potential.
The history of neuromyelitis optica.
Induction of pluripotent stem cells from adult human fibroblasts by defined factors.
Combined sequence-based and genetic mapping analysis of complex traits in outbred rats.
Gateway to wellness: an occupational therapy collaboration with the national multiple sclerosis society.
Bupropion-Related Visual Hallucinations in a Veteran With Posttraumatic Stress Disorder and Multiple Sclerosis.
Monitoring medication adherence in multiple sclerosis using a novel web-based tool: A pilot study.
Stem cell therapy for central nerve system injuries: glial cells hold the key.
An analytical model for estimating water exchange rate in white matter using diffusion MRI.
The discovery of natalizumab, a potent therapeutic for multiple sclerosis.
Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice.
The precise chemical-physical nature of the pharmacore in FK506 binding protein inhibition: ElteX, a new class of nanomolar FKBP12 ligands.
Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod.
Fingolimod targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-γ production in CD8(+) lymphocytes.
The Immunomodulatory and Neuroprotective Effects of Mesenchymal Stem Cells (MSCs) in Experimental Autoimmune Encephalomyelitis (EAE): A Model of Multiple Sclerosis (MS).
Arterial, venous and other vascular risk factors in multiple sclerosis.
Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design.
The grey matter correlates of impaired decision-making in multiple sclerosis.
K(+) channel alterations in the progression of experimental autoimmune encephalomyelitis.
GeNeuro Announces the Launch of Phase IIb Proof-of-Concept Study with GNbAC1 in Multiple Sclerosis and Servier Equity Investment
PML in MS Patients Making Natalizumab-to-Fingolimod Switch

Pages